Literature DB >> 17329463

Schizophrenia and co-occurring substance use disorder.

Alan I Green1, Robert E Drake, Mary F Brunette, Douglas L Noordsy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17329463     DOI： 10.1176/ajp.2007.164.3.402

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


× No keyword cloud information.
  27 in total

1.  Training in Substance-Related and Addictive Disorders, Part 1: Overview of Clinical Practice and General Recommendations.

Authors:  Gilles Fleury; Robert Milin; David Crockford; Leslie Buckley; Dara Charney; Tony P George; Nady el-Guebaly
Journal:  Can J Psychiatry       Date:  2015-12       Impact factor: 4.356

2.  Psychosocial treatment programs for people with both severe mental illness and substance misuse.

Authors:  M Cleary; G E Hunt; S Matheson; N Siegfried; G Walter
Journal:  Schizophr Bull       Date:  2008-01-29       Impact factor: 9.306

Review 3.  Pharmacological treatment of schizophrenia and co-occurring substance use disorders.

Authors:  David A Smelson; Lisa Dixon; Thomas Craig; Stephen Remolina; Steven L Batki; Noosha Niv; Richard Owen
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 4.  Violent behaviour among people with schizophrenia: a framework for investigations of causes, and effective treatment, and prevention.

Authors:  Sheilagh Hodgins
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2008-08-12       Impact factor: 6.237

5.  Changing the landscape of an urban public mental health system: the 2008 New York State/New York City Mental Health-Criminal Justice Review Panel.

Authors:  Thomas E Smith; Lloyd I Sederer
Journal:  J Urban Health       Date:  2010-01       Impact factor: 3.671

6.  Integrated Dual Disorder Treatment Implementation in a Large State Sample.

Authors:  Jennifer Harrison; Amy Curtis; Linwood Cousins; Jessaca Spybrook
Journal:  Community Ment Health J       Date:  2016-05-28

Review 7.  Β-Amyloid Burden is Not Associated with Cognitive Impairment in Schizophrenia: A Systematic Review.

Authors:  Jun Ku Chung; Shinichiro Nakajima; Eric Plitman; Yusuke Iwata; Danielle Uy; Philip Gerretsen; Fernando Caravaggio; M Mallar Chakravarty; Ariel Graff-Guerrero
Journal:  Am J Geriatr Psychiatry       Date:  2016-04-29       Impact factor: 4.105

8.  Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers.

Authors:  Erik T te Beek; Justin L Hay; Jonathan N Bullman; Clare Burgess; Kimberly J Nahon; Erica S Klaassen; Frank A Gray; Joop M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

Review 9.  An Integrative Perspective on the Role of Dopamine in Schizophrenia.

Authors:  Tiago V Maia; Michael J Frank
Journal:  Biol Psychiatry       Date:  2016-06-01       Impact factor: 13.382

10.  Changes in motivation for treatment in precontemplating dually diagnosed patients receiving assertive community treatment.

Authors:  H E Kortrijk; C L Mulder; D van Vliet; C van Leeuwen; E Jochems; A B P Staring
Journal:  Community Ment Health J       Date:  2013-01-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.